… crucial in the progression from primary to metastatic prostate cancer (PC) and subsequently,
in the … In large phase 3 trials and in the clinical practice setting, oral abiraterone acetate in …

… Abiraterone acetate plus prednisone significantly improves radiographic progression-free …
patients with metastatic castration-resistant prostate cancer compared with prednisone alone. …

… of the systemic treatment of prostate cancer is that the … prostate cancer (CRPC). The current
paper reviews the rationale, mechanism of action and clinical data of abiraterone acetate, an …

… study, the addition of abiraterone acetate plus prednisone to androgen … prostate cancer
(mCSPC). Here, we present long-term survival outcomes and safety of abiraterone acetate plus …

… bone metastases in prostate cancer might also positively … abiraterone acetate can improve
pain and manifestations of bone metastases in metastatic castration-resistant prostate cancer …

… -naive metastatic castration-resistant prostate cancer (COU-AA-302 trial); … -naive prostate
cancer, the phase 3 LATITUDE study was done to evaluate the addition of abiraterone acetate …

… may have received subsequent prostate cancer therapy before receiving abiraterone acetate
plus … progression (366 [68%] patients in the abiraterone acetate group and 370 [69%] in the …

… prostate cancer who received abiraterone acetate at doses of 250 to 2,000 mg daily. The
right panel shows mean corticosterone levels at day 28 by abiraterone acetate dose [12]. …

PURPOSE Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease
with current standard-of-care therapies. Homologous recombination repair (HRR) gene …

… Abiraterone acetate and enzalutamide both improve outcomes in patients with metastatic
castration-resistant prostate cancer (mCRPC). Optimal sequencing for these agents and …